China Meheco Group Co

China Meheco Group Co R&D per Employee

The R&D Spending per Employee of China Meheco Group Co (600056.SS) as of Oct 28, 2026 is 19,051.56 CNY. In the previous year, R&D Spending per Employee was 16,862.59 CNY — a change of 12.98% (higher).

R&D per Employee

19,051.56CNY

YoY

12.98%

Last updated:

R&D Spending per Employee of China Meheco Group Co is 2025 19,051.56 CNY. R&D Spending per Employee of China Meheco Group Co was 2024 16,862.59 CNY. It decreases by 12.98% higher compared to the previous year.

The China Meheco Group Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
10,344.89 CNY
Jan 1, 2019
12,936.80 CNY
Jan 1, 2020
10,080.40 CNY
Jan 1, 2021
6,902.68 CNY
Jan 1, 2022
9,302.17 CNY
Jan 1, 2023
13,898.39 CNY
Jan 1, 2024
16,862.59 CNY
Jan 1, 2025
19,051.56 CNY
The China Meheco Group Co R&D per Employee history
YEARR&D per EmployeeYoY
19,051.56CNY+12.98%
16,862.59CNY+21.33%
13,898.39CNY+49.41%
9,302.17CNY+34.76%
6,902.68CNY-31.52%
10,080.40CNY-22.08%
12,936.80CNY+25.06%
10,344.89CNY-40.19%
17,294.94CNY+75.99%
9,827.34CNY+10.28%
8,911.13CNY+39.89%
6,370.30CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

China Meheco Group Co Stock analysis

What does China Meheco Group Co do? China Meheco Group Co., Ltd. generates revenue through its Industrial Pharmaceutical segment, which manufactures and distributes chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces. The Commercial Pharmaceutical segment focuses on wholesale and distribution of pharmaceuticals and medical devices. The Trading segment handles international exporting and medical resourcing introduction. The company serves healthcare providers, hospitals, and pharmacies through its wholesale operations, targeting the pharmaceutical and medical device markets in China and internationally. The Industrial Pharmaceutical segment produces chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces for distribution. The Commercial Pharmaceutical segment supplies pharmaceuticals and medical devices to healthcare institutions and retailers. The Trading segment facilitates international exports of pharmaceutical products and introduces medical resources globally, catering to global healthcare markets. China Meheco's revenue streams are derived from the sale of pharmaceutical products across its three segments. The Industrial segment manufactures and sells chemical and traditional Chinese medicine products, while the Commercial segment distributes these products through wholesale channels. The Trading segment earns from exporting pharmaceuticals and managing international medical resource procurement for global clients. China Meheco Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about China Meheco Group Co stock

R&D Spending per Employee of China Meheco Group Co is 19,051.56 CNY in 2025.

R&D Spending per Employee of China Meheco Group Co changed from 16,862.59 CNY to 19,051.56 CNY, representing a 12.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee China Meheco Group Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's China Meheco Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — China Meheco Group Co

All Key Metrics — China Meheco Group Co